等待开盘 07-23 09:30:00 美东时间
0.000
0.00%
<p>InflaRx N.V. announced the termination of its Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) due to futility, based on an interim analysis of 30 patients. The company will focus on developing INF904, an oral C5aR inhibitor, with data expected this summer. Vilobelimab remains available for COVID-19 under EU and U.S. authorizations.</p>
05-28 05:30
Cuprina计划以每股4-4.5美元的价格发行380万股股票,以筹资1600万美元。
2024-09-04 15:13
证券之星消息,根据企查查数据显示,近日科大讯飞股份有限公司新提交“讯飞星火 IFLYTEK SPARK”等2件商标注册申请。商标申请详情如下: 今年以来科大讯...
2023-12-27 12:54